Moleculin Biotech, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Moleculin Biotech announced that the Mexican Patent Office granted Patent No. 436849 protecting the company's lung-targeted liposomal Annamycin formulation, valid through November 23, 2040. The patent strengthens Moleculin's global IP portfolio for Annamycin, its lead Phase 2/3 stage anthracycline candidate currently in the MIRACLE trial for relapsed/refractory acute myeloid leukemia. No financial terms, counterparties, or material business changes are disclosed; this is a routine IP milestone announcement.
Why this rating
Patent grant is routine IP housekeeping for a clinical-stage biotech. No deal, financing, clinical data, or commercial terms. Annamycin still in Phase 2/3; patent value uncertain pre-approval. Small relative to $8.8M market cap.
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.